Cellectar Biosciences Stock Revenue
| CLRB Stock | USD 0.30 0.98 76.27% |
Cellectar Biosciences fundamentals help investors to digest information that contributes to Cellectar Biosciences' financial success or failures. It also enables traders to predict the movement of Cellectar Stock. The fundamental analysis module provides a way to measure Cellectar Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cellectar Biosciences stock.
| Last Reported | Projected for Next Year |
Cellectar | Revenue |
Cellectar Biosciences Company Revenue Analysis
Cellectar Biosciences' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Cellectar
Projected quarterly revenue analysis of Cellectar Biosciences provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Cellectar Biosciences match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Cellectar Biosciences' stock price.
Cellectar Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Cellectar Biosciences is extremely important. It helps to project a fair market value of Cellectar Stock properly, considering its historical fundamentals such as Revenue. Since Cellectar Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cellectar Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cellectar Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Cellectar Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Cellectar Biosciences reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Cellectar Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cellectar Biosciences' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cellectar Biosciences could also be used in its relative valuation, which is a method of valuing Cellectar Biosciences by comparing valuation metrics of similar companies.Cellectar Biosciences is currently under evaluation in revenue category among its peers.
Cellectar Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Cellectar Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cellectar Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cellectar Biosciences' value.| Shares | State Street Corp | 2024-09-30 | 116.8 K | Northern Trust Corp | 2024-09-30 | 61.1 K | Xtx Topco Ltd | 2024-09-30 | 53 K | Jane Street Group Llc | 2024-06-30 | 41.9 K | Raymond James Finl Svs Advisors, Inc. | 2024-09-30 | 30 K | Pale Fire Capital Se | 2024-09-30 | 25 K | Sequoia Financial Advisors Llc | 2024-09-30 | 23.8 K | Jpmorgan Chase & Co | 2024-09-30 | 23.2 K | Two Sigma Securities, Llc | 2024-09-30 | 22.8 K | Rosalind Advisors, Inc. | 2024-09-30 | 3.7 M | Aigh Capital Management, Llc | 2024-09-30 | 3.2 M |
Cellectar Fundamentals
| Return On Equity | -7.97 | ||||
| Return On Asset | -1.66 | ||||
| Current Valuation | 35.58 M | ||||
| Shares Outstanding | 41.27 M | ||||
| Shares Owned By Insiders | 2.83 % | ||||
| Shares Owned By Institutions | 34.54 % | ||||
| Number Of Shares Shorted | 1.16 M | ||||
| Price To Earning | (1.35) X | ||||
| Price To Book | 35.96 X | ||||
| EBITDA | (38.77 M) | ||||
| Net Income | (37.98 M) | ||||
| Cash And Equivalents | 24.81 M | ||||
| Cash Per Share | 4.06 X | ||||
| Total Debt | 552.98 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 4.51 X | ||||
| Book Value Per Share | (0.96) X | ||||
| Cash Flow From Operations | (32.38 M) | ||||
| Short Ratio | 8.34 X | ||||
| Earnings Per Share | (1.41) X | ||||
| Target Price | 13.25 | ||||
| Number Of Employees | 20 | ||||
| Beta | 1.01 | ||||
| Market Capitalization | 55.71 M | ||||
| Total Asset | 12.08 M | ||||
| Retained Earnings | (217.48 M) | ||||
| Working Capital | (2.48 M) | ||||
| Current Asset | 8.14 M | ||||
| Current Liabilities | 1.39 M | ||||
| Net Asset | 12.08 M |
About Cellectar Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cellectar Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cellectar Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cellectar Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cellectar Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cellectar Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cellectar Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cellectar Biosciences Stock:Check out Cellectar Biosciences Piotroski F Score and Cellectar Biosciences Altman Z Score analysis. For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. If investors know Cellectar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cellectar Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.41) | Return On Assets (1.66) | Return On Equity (7.97) |
The market value of Cellectar Biosciences is measured differently than its book value, which is the value of Cellectar that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectar Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cellectar Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cellectar Biosciences' market value can be influenced by many factors that don't directly affect Cellectar Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cellectar Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectar Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectar Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.